Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Upstream Bio, Inc. ( (UPB) ) is now available.
On February 11, 2026, Upstream Bio reported positive top-line results from its Phase 2 VALIANT trial of verekitug in 478 adults with severe asthma, showing statistically significant and clinically meaningful reductions in annualized asthma exacerbation rates with both 100 mg every 12 weeks and 400 mg every 24 weeks compared with placebo. The study also demonstrated placebo-adjusted improvements in lung function and marked reductions in exhaled nitric oxide at week 60, with a generally favorable safety profile and more than 90% of eligible patients rolling into the long-term VALOUR extension study, positioning verekitug as a potentially differentiated, less-frequently dosed biologic as the company prepares Phase 3 programs in severe asthma and CRSwNP while continuing a Phase 2 COPD trial.
The most recent analyst rating on (UPB) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Upstream Bio, Inc. stock, see the UPB Stock Forecast page.
Spark’s Take on UPB Stock
According to Spark, TipRanks’ AI Analyst, UPB is a Neutral.
The score is driven primarily by strong technical momentum (price above key moving averages with positive MACD and supportive RSI). This is tempered by weak financial performance typical of an early-stage biotech—expanding losses and worsening cash burn—despite a low-debt balance sheet. Valuation is also constrained by negative earnings (negative P/E) and no stated dividend yield.
To see Spark’s full report on UPB stock, click here.
More about Upstream Bio, Inc.
Upstream Bio, Inc. is a Nasdaq-listed, clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders such as severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and COPD. Its lead product candidate is verekitug, a fully human monoclonal antibody that antagonizes the thymic stromal lymphopoietin (TSLP) receptor to modulate upstream inflammatory pathways in allergic and inflammatory diseases.
Average Trading Volume: 585,306
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.42B
See more insights into UPB stock on TipRanks’ Stock Analysis page.